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Abstract
Background In Australia, there is voluntary reporting of
suspected adverse events (AEs) of therapeutic medicines.
Some dopamine agonists (DAs) have serious AEs.
Objective We aimed to explore the pattern of DA AE
reporting over two decades.
Methods We analysed AE case line listings obtained
from the Australian Committee on the Safety of Medicines
(ACSOM) for bromocriptine, cabergoline, pergolide,
pramipexole and ropinirole, and related these to drug
utilisation data (1992–2012). We noted the AE nature,
frequency, onset, novelty, severity and outcome.
Results The 220 suspected AEs fell into five categories:
(i) syncopal/pre-syncopal, (ii) fibrotic, (iii) psychotic, (iv)
obsessive-compulsive behaviours (OCB) and (v) increased
sleep. There were differential lag times between initial
individual drug registration and reporting of suspected
AEs, with a lag of at least one year for fibrotic reactions
and OCB compared to more contemporaneous reporting of
other AEs. Consistent with the published literature,
ACSOM data showed that ergot DAs share fibrotic reac-
tions as a class AE, whereas symptomatic hypotensive
reactions, psychosis and OCB occurred in both ergot and
non-ergot DAs, cabergoline and pramipexole, respectively.
Reports of syncopal and pre-syncopal reactions seemed to
diminish as ergot-based DA use declined. Levodopa was
taken simultaneously with DAs in 87 instances. Of those
treated, 92 % were 50 years or older. Parkinson’s disease
accounted for 89 % of use (119 reports).
Conclusions Exploring the temporal relationship between
post-marketing AE reporting and utilisation data, as
exemplified by DAs, can be a valuable pharmacovigilance
tool to encourage targeted adverse event monitoring and
reporting.
Key Points
The pattern of adverse event reporting of dopamine
agonists (DAs) in Australia was previously
unknown.
Ergot DAs shared fibrotic reactions as a class
adverse effect (AE), whereas symptomatic
hypotensive reactions, psychosis and obsessive-
compulsive behaviours occurred in both ergot and
non-ergot DAs.
Exploring the temporal relationship between post-
marketing AE reporting and utilisation data can be a
valuable pharmacovigilance tool to encourage
targeted adverse event monitoring and reporting.
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1 Introduction
Dopamine agonists (DAs) can be broadly subdivided into
ergot derivatives (e.g. bromocriptine, cabergoline, per-
golide) and non-ergot derivatives (ropinirole, pramipexole,
apomorphine and rotigotine. While effective in the control
of Parkinson’s disease, their use has recently decreased in
Australia [1], probably reflecting caution after unusual
adverse effects with ergot-derived DAs were reported.
These include abrupt onset of sleep in inappropriate cir-
cumstances [2–4], compulsive behaviours [5–7] and
fibrotic reactions [8–10]. The former Australian Adverse
Drug Reaction Bulletin reported on pathological gambling
with cabergoline in 2005 [11] and fibrotic reactions with
ergot derivatives in 2006 [12]. In 2007, the US Food and
Drug Administration issued a Public Health Advisory for
pergolide, which was withdrawn from the US market
shortly afterward [13]. Such unfavourable press has prob-
ably contributed to increased use of the recently available
non-ergot DA, pramipexole. Directly acting DAs were
registered for use in Australia by the Therapeutic Goods
Administration (TGA) from the 1990s: bromocriptine (pre-
1992), pergolide (1994), cabergoline (2000), rotigotine
(2007), ropinirole (2008) and pramipexole (2008).
Although comparison of AEs associated with DAs have
been evaluated elsewhere [7, 14, 15], there have been no
published studies of post-marketing adverse events (AEs)
across the class of dopamine agonists in Australia. We
aimed to explore the pattern of AE reporting of DAs
received by Australian regulatory authorities.
2 Methods
A voluntary post-marketing mechanism exists whereby
health professionals and consumers may report suspected
adverse effects of therapeutic medicines to the Australian
Committee on the Safety of Medicines (ACSOM), part of
the TGA in the Australian Government Department of
Health. The TGA maintains the Database of Adverse Event
Notifications (DAEN: http://www.tga.gov.au/daen/daen-
entry.aspx). We analysed the de-identified DAEN case
details for bromocriptine, cabergoline, pergolide,
pramipexole and ropinirole—the most widely used directly
acting DAs in Australia from 1992 to 2012. As the cost of
rotigotine prescriptions was only subsidised from May
2013 (outside the study period) and reports of AEs were
low; this medicine was excluded from review. There was
also too little apomorphine use to warrant consideration.
AE reports may contain data on: date of event, sex, age,
outcome (recovered or not), polypharmacy, onset time and
(nature of) reaction; however, information supplied is
sometimes incomplete. We were not able to access any
information on dose for reported medicines.
Pharmacovigilance data for included DAs were related
to drug utilisation data for the same period (2002–2012).
DA use was reported as annual dispensed prescriptions
under the Pharmaceutical Benefits (PBS) or Repatriation
Pharmaceutical Benefits (RPBS) Schemes and from esti-
mated non-subsidised (i.e. under general co-payment and
private) prescribing. As ropinirole is not subsidised by
these Schemes and available only on private prescription,
use was low during the study period. It was therefore
excluded from utilisation review. Patterns of adverse
reaction reporting were related to annual use of individual
agonists. Although bromocriptine was available in Aus-
tralia prior to 1992, we could not access AE reports before
that time.
3 Results
A considerable variety of possible adverse effects was
reported. Here only the more common (ten or more
instances) and novel reactions are considered. They fall
into five main categories: (i) syncopal or pre-syncopal (i.e.
hypotensive); (ii) fibrotic (lung, pleura (±effusion), peri-
cardium, abdominal cavity and retroperitoneal, heart
valves); (iii) psychotic (including hallucinations, confu-
sion); (iv) obsessive-compulsive behaviours (OCBs;
pathological gambling, hypersexuality, punding [16]; and
(v) increased sleep (somnolence, abrupt onset sleep). There
were 220 reports of such adverse reactions between 1992
and 2012 (Table 1). It should be noted that a single AE
report may have involved more than one symptom and that
two DAs were co-administered in eight reports. Conse-
quently, total report numbers and numbers of individual
adverse effects do not reconcile. Levodopa was taken
simultaneously with DAs in 87 instances. The patient’s age
was recorded in 83 of these 87, with 92 % being 50 years
or older and, of 78 cases, 33 % were female. In contrast, of
the 102 patients not taking levodopa whose ages were
recorded, 67 % were 50 years or older. The indications for
which the medicines had been used were noted in 119 of
these reports: Parkinson’s disease, 106; restless legs, four;
and endocrine purposes including lactation suppression,
nine.
In the 1990s, bromocriptine was the dominant DA and
pergolide use was low (Fig. 1, upper panel). From a peak in
the early 1990s, bromocriptine prescriptions declined
steadily. Cabergoline use peaked in the mid-2000s, but
then decreased as pramipexole was introduced in 2007 and
its use thereafter increased dramatically. Ropinirole non-
subsidised use was very low, and constituted about two-
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thirds of pergolide subsidised and non-subsidised use in the
period 2008–2010.
There was a general increase in the reporting of AEs
over time (Fig. 1, lower panel). Reports of hypotension
remained low and stable during the 1990s, peaked in 2007,
and then quickly declined, coinciding with pramipexole
replacing cabergoline use. Reports of OCB AEs began in
2003 and, apart from two dips (2004 and 2010), increased
to a peak in 2012. This coincides with peaking cabergoline
and then pramipexole use. Psychotic reactions peaked in
2009 then declined, which correlated with decreased
cabergoline and increased pramipexole use. The associa-
tion of long-term therapy with ergot-derived DAs and
fibrotic reactions is well recognised [17–19], with a peak of
reports in 2005 and subsequent decline. It is difficult to
determine whether the fewer reports reflect the steady
decline in prescribing of bromocriptine since the 1990s, or
cabergoline, or both. Fibrotic reactions tend to take several
years to manifest. Thus, this association probably prompted
the decline of bromocriptine and cabergoline prescribing
(pergolide use being already significantly less than the
others), and may have promoted the rapid growth of
pramipexole use.
With regard to reaction onset, 77 % of hypotensive
problems occurred within the first week of DA therapy,
whereas 67 % of fibrotic reactions were not recognised
until at least one year after therapy initiation. Some 34 %
of the psychotic reactions occurred in the initial week of
medicine intake, and 54 % within the first month; however,
15 % took more than a year to be recognised. OCB AEs
was noted within the first 6 months for only 25 %; in half,
the medicines had been used for at least one year. Sleep
disturbances were too infrequent to warrant further con-
sideration, but we noted there were five instances of abrupt-
onset sleep—three associated with cabergoline, one with
pergolide and one with pramipexole.
There appears to be an under-reporting of levodopa co-
therapy in the reports. Use of DA monotherapy for endo-
crine disorders is likely to be small. For example, lactation
suppression would only account for a few days of low dose
use. The long-term use of DAs as sole therapy for pro-
lactinoma is also rare compared to their use in movement
disorders. This case recording anomaly is supported by
two-thirds of the reported DA monotherapy patients being
in the Parkinsonian age group (i.e. 50? years), with ages
Table 1 Reported adverse
effects in two classes (ergot and
non-ergot derivatives) and five
main categories associated with
dopamine agonists
Adverse effects Ergot derivatives Non-ergot derivatives
Bromocriptine
N = 62
Pergolide
N = 29
Cabergoline
N = 95
Pramipexole
N = 29
Ropinirolea
N = 12
n % n % n % n % N %
Hypotension 17 27 7 24 6 6 2 7 4 33
Fibrosis 15 24 6 21 26 27 0 0 0 0
Psychosis 28 45 7 24 26 27 24 83 4 33
Obsessive-compulsive behaviour 0 0 4 14 32 34 5 17 3 25
Sleep excess 2 3 2 7 4 4 2 7 0 0
a Ropinirole was not subsidised during the study period
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Fig. 1 Use of dopamine agoninsts (DAs) and frequency of reported
adverse effects between 1992 and 2012. Upper panel dispensed
prescriptions of bromocriptine, pergolide, cabergoline and pramipex-
ole. Lower panel reports of DAs associated with hypotension, fibrosis,
psychotic disturbances and obsessive-compulsive behaviours [ropi-
nirole was not subsidised during the study period]
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un-recorded in 4.6 % of those reported as taking levodopa,
but in 12.7 % of those not taking it. Hence, the role of
dopamine formed from levodopa in contributing to adverse
effects cannot be elucidated from these data.
4 Discussion
Although reporting rates have increased over time; only a
small proportion of AEs are actually reported to national
reporting centres [20]. Under-reporting appears to be a
consistent concern for studies in pharmacovigilance [15].
In an attempt to improve transparency and offset the low
reporting rates from health professionals, Australian con-
sumers have been recognised as active partners in phar-
macovigilance since 2000. The TGA report options include
mailing a ‘blue card’ or using the web link (https://www.
ebs.tga.gov.au/ebs/ADRS/ADRSRepo.nsf?OpenDatabase)
or the national consumer Adverse Medicine Events (AME)
Line [21]. Despite these options, there remains not only
low awareness of available reporting systems but also
limited promotion on how to use them [22].
There were differential lag times between the individual
DA being marketed and reporting of individual suspected
AEs: at least one year for fibrotic reactions and OCBs,
whereas the other adverse effects appear to be more con-
temporaneous. Fibrotic reactions appear to be class-type
AEs of ergot-derived DAs, whereas symptomatic
hypotensive reactions, psychosis and OCBs have occurred
in both an ergot and a non-ergot DA (cabergoline and
pramipexole, respectively). Although these data appear
plausible and consonant with clinical experience, at least
two questions arise.
Firstly, how representative of the true situation in the
community are these data? Analysis and commentary of
AE reporting depends on the initiative of individual prac-
titioners, patients and others concerned with patient wel-
fare. There is likely to be disproportionate reporting of AEs
that appear novel or dangerous to the patient [23–25].
Publicity about a newly recognised and perhaps surprising
AE, such as pathological gambling or abruptly falling
asleep in potentially hazardous situations, is likely to
encourage reporting. In contrast, subsequent familiarity
with such AEs may reduce the motivation to report. It is
impossible to know, from the available data, whether the
decrease in reporting of psychotic behaviour associated
with pramipexole can be explained by disproportionate
under-reporting or a low incidence of occurrence of this
AE. This alludes to the ‘notoriety bias’ which was also
identified by Pariente et al. [26], i.e. the increased reporting
of AEs following safety alerts.
Secondly, is cabergoline the only medication among the
ergot-based DAs associated with OCBs? Such behaviours
may have been too rare to be recognised as medicine-re-
lated for the older ergot-based agonists. They may have
been reported disproportionately when their nature and
relation to the therapeutic class were identified.
There is also uncertainty about the possible added
effects of dopamine derived from co-administered levo-
dopa in a number of cases. Despite the limitations in the
data, the AE profile of the non-ergot pramipexole appeared
to differ from those of the ergot-based DAs.
Consistent with the published literature, these data
showed that ergot DAs share fibrotic reactions as a class
AE. The remaining categories of AEs relate to individual
medicines rather than a subclass. Unfortunately, the rela-
tively low number of AE reports submitted for DAs in
Australia precluded further sub-group analysis. Exploring
the relationship between post-marketing AE reporting and
utilisation data, as exemplified by DAs, can be a valuable
pharmacovigilance tool. Individual AEs with medicines
within a therapeutic class appear to have differential lag
times between the medicine being marketed and suspicion
of a causal link. Contributing factors include the inherent
nature of the AE, reaction novelty and severity, and fre-
quency of medicine use. This time lag also appears to differ
for subjective versus objectively measurable symptoms and
signs. Prospective consideration of likely temporal report-
ing patterns across individual medicines and therapeutic
classes could, however, contribute to risk reduction by
proactive encouragement of monitoring and reporting of
AEs when such events are most likely to manifest.
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